Cargando…
New developments in acne treatment: role of combination adapalene–benzoylperoxide
The fixed-dose combination adapalene 0.1%/benzoylperoxide 2.5% (A/BPO) was introduced as an acne vulgaris therapeutic in 2007. It combines anti-inflammatory, keratolytic, comedolytic, and antibacterial properties. Thus, it addresses several pathophysiological factors involved in the pathophysiology...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055040/ https://www.ncbi.nlm.nih.gov/pubmed/27757036 http://dx.doi.org/10.2147/TCRM.S94062 |
_version_ | 1782458713350602752 |
---|---|
author | Kim, Su Youn Ochsendorf, Falk R |
author_facet | Kim, Su Youn Ochsendorf, Falk R |
author_sort | Kim, Su Youn |
collection | PubMed |
description | The fixed-dose combination adapalene 0.1%/benzoylperoxide 2.5% (A/BPO) was introduced as an acne vulgaris therapeutic in 2007. It combines anti-inflammatory, keratolytic, comedolytic, and antibacterial properties. Thus, it addresses several pathophysiological factors involved in the pathophysiology of acne. This review highlights the rationale for the use of this fixed-dose combination product, its therapeutic efficacy including effects on adherence and quality of life, its use for different forms of acne, and the side-effect profile. In summary, the fixed-dose combination of A/BPO gel can be regarded as a highly effective and safe formulation. It is not associated with antibiotic resistance. It reduces factors that cause nonadherence and has positive effects on the quality of life of affected patients. The tolerance is good. The initial mild irritation potential can be addressed by adequate counseling. A/BPO can be used for all forms of inflammatory acne, including severe forms, as part of a combination with systemic antibiotics. Finally, it can also be used for the long-term treatment of chronic acne. Thus, it is a very valuable therapeutic option in daily practice, which is reflected by its strong recommendation in the “European S3-guidelines”. |
format | Online Article Text |
id | pubmed-5055040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50550402016-10-18 New developments in acne treatment: role of combination adapalene–benzoylperoxide Kim, Su Youn Ochsendorf, Falk R Ther Clin Risk Manag Review The fixed-dose combination adapalene 0.1%/benzoylperoxide 2.5% (A/BPO) was introduced as an acne vulgaris therapeutic in 2007. It combines anti-inflammatory, keratolytic, comedolytic, and antibacterial properties. Thus, it addresses several pathophysiological factors involved in the pathophysiology of acne. This review highlights the rationale for the use of this fixed-dose combination product, its therapeutic efficacy including effects on adherence and quality of life, its use for different forms of acne, and the side-effect profile. In summary, the fixed-dose combination of A/BPO gel can be regarded as a highly effective and safe formulation. It is not associated with antibiotic resistance. It reduces factors that cause nonadherence and has positive effects on the quality of life of affected patients. The tolerance is good. The initial mild irritation potential can be addressed by adequate counseling. A/BPO can be used for all forms of inflammatory acne, including severe forms, as part of a combination with systemic antibiotics. Finally, it can also be used for the long-term treatment of chronic acne. Thus, it is a very valuable therapeutic option in daily practice, which is reflected by its strong recommendation in the “European S3-guidelines”. Dove Medical Press 2016-10-03 /pmc/articles/PMC5055040/ /pubmed/27757036 http://dx.doi.org/10.2147/TCRM.S94062 Text en © 2016 Kim and Ochsendorf. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Kim, Su Youn Ochsendorf, Falk R New developments in acne treatment: role of combination adapalene–benzoylperoxide |
title | New developments in acne treatment: role of combination adapalene–benzoylperoxide |
title_full | New developments in acne treatment: role of combination adapalene–benzoylperoxide |
title_fullStr | New developments in acne treatment: role of combination adapalene–benzoylperoxide |
title_full_unstemmed | New developments in acne treatment: role of combination adapalene–benzoylperoxide |
title_short | New developments in acne treatment: role of combination adapalene–benzoylperoxide |
title_sort | new developments in acne treatment: role of combination adapalene–benzoylperoxide |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055040/ https://www.ncbi.nlm.nih.gov/pubmed/27757036 http://dx.doi.org/10.2147/TCRM.S94062 |
work_keys_str_mv | AT kimsuyoun newdevelopmentsinacnetreatmentroleofcombinationadapalenebenzoylperoxide AT ochsendorffalkr newdevelopmentsinacnetreatmentroleofcombinationadapalenebenzoylperoxide |